Origins and molecular effects of hypoxia in cancer

IF 12.1 1区医学 Q1 ONCOLOGY

Seminars in cancer biology Pub Date : 2024-10-18 DOI:10.1016/j.semcancer.2024.10.001

Sergio Rey-Keim , Luana Schito

引用次数: 0

Abstract

Hypoxia (insufficient O₂) is a pivotal factor in cancer progression, triggering genetic, transcriptional, translational and epigenetic adaptations associated to therapy resistance, metastasis and patient mortality. In this review, we outline the microenvironmental origins and molecular mechanisms responsible for hypoxic cancer cell adaptations in situ and in vitro, whilst outlining current approaches to stratify, quantify and therapeutically target hypoxia in the context of precision oncology.

查看原文本刊更多论文

癌症中缺氧的起源和分子效应。

缺氧（氧气不足）是癌症进展的关键因素，会引发与耐药性、转移和患者死亡率相关的遗传、转录、转化和表观遗传适应。在这篇综述中，我们将概述原位和体外导致缺氧性癌细胞适应性的微环境起源和分子机制，同时概述目前在精准肿瘤学背景下对缺氧进行分层、量化和靶向治疗的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in cancer biology 医学-肿瘤学

CiteScore

26.80

自引率

4.10%

发文量

347

审稿时长

15.1 weeks

期刊介绍： Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field. The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies. To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area. The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.